|Bid||75.14 x 800|
|Ask||75.56 x 1000|
|Day's range||74.89 - 75.54|
|52-week range||61.05 - 82.25|
|Beta (3Y monthly)||1.09|
|PE ratio (TTM)||25.61|
|Earnings date||25 Jul 2019|
|Forward dividend & yield||0.76 (1.00%)|
|1y target est||82.93|
Baxter (BAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Synchrony Financial announced before the opening bell Thursday that it will increase its quarterly dividend by a penny, following dividend increases by Phillips 66 and Baxter International.
Baxter International Inc. (BAX), a leading global medical products company, today announced that representatives of the company will conduct a series of Fixed Income Investor Presentations on Thursday, May 9, 2019.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Many investors are still learning about the various metrics that can be useful when analysing a stock...
Baxter International Inc. (BAX), a leading global medical products company, announced today that it has been named a 2019 Best Company for Multicultural Women by Working Mother magazine. This recognition is a result of the company’s sustained focus on supporting and advancing multicultural women at all levels of the organization globally.
Baxter International Inc. , a leading global medical products company, today announced an increase in the company’s quarterly cash dividend, to a rate of $0.22 per share of common stock.
Baxter International Inc. (BAX), a leading global medical products company, will present at the UBS Global Healthcare Conference on Monday, May 20, 2019 in New York. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 1:00 p.m. Eastern Time.
Baxter International Inc. (BAX), a global leader in renal care, along with the National Association for the Advancement of Colored People (NAACP) and the Alliance for Home Dialysis, today announced that the Dialysis Health Imperative for Access, Choice, and Equity (ACE) program will be expanded for a third year. This year, the program is expected to reach even more individuals and focus on driving awareness of kidney disease—including risk factors, prevention strategies and home dialysis treatment options—among the African American community.
Higher revenues, growth in APAC and strong operating margin benefit Baxter's (BAX) Q1 earnings. However, weak performance at Medication Delivery and Clinical Nutrition remains a concern.
On a per-share basis, the Deerfield, Illinois-based company said it had net income of 66 cents. Earnings, adjusted for non-recurring costs, came to 76 cents per share. The results beat Wall Street expectations. ...
DEERFIELD, Ill.-- -- First-quarter revenue of $2.6 billion declined 2 percent on a reported basis and increased 2 percent on an operational basis First-quarter GAAP earnings per share of $0.66; Adjusted EPS of $0.76 increased 9 percent Company now expects full-year 2019 Adjusted EPS of $3.27 to $3.35 1 Baxter International Inc. , a leading global medical products company, today reported results for ...
Baxter (BAX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Strong performance across Renal Care, Clinical Nutrition, Advanced Surgery and Acute Therapies businesses might aid Baxter (BAX) in Q1. However, lower sales at Pharmaceutical business might be a woe.
Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Could Apple and Qualcomm’s Settlement Mean Upside for Point72?Steve Cohen’s Point72 Management Steve Cohen is a very high-profile investor whose SAC capital returned 30% annually for more than 20 years. In 2012, the firm was found guilty of
Baxter International Inc. (BAX), a leading global medical products company, will present at the 2019 Bank of America Merrill Lynch Health Care Conference in Las Vegas on May 15, 2019. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 8:40 a.m. Pacific Time. With products, technologies and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations.
Baxter International Inc. (NYSE:BAX) is a stock with outstanding fundamental characteristics. When we build an investment case, we need to look at the stock with a holistic perspective. In the case of BAX, it...
Baxter International Inc. (BAX), a global leader in advancing surgical innovation, today announced that it has received U.S. Food and Drug Administration (FDA) approval for faster preparation of its leading hemostatic product, Floseal Hemostatic Matrix, at the 2019 Association of periOperative Registered Nurses (AORN) Global Surgical Conference and Expo. This next generation of Floseal has 20 percent fewer components and steps to prepare,1 making it easier and faster for operating room (OR) nurses to get Floseal in the hands of surgeons to help stop bleeding during procedures. The new design will be on display at Baxter’s AORN booth #1624.
Baxter International Inc. (BAX), a leading global medical products company, will host a webcast of its Annual Meeting of Stockholders on Tuesday, May 7, 2019 at 9 a.m. Central Daylight Time. The live webcast of Baxter’s presentation along with the accompanying slides will be accessible from Baxter’s website at www.baxter.com.